中华肝脏病杂志最新文献

{"title":"[Effect of switching from entecavir to tenofovir amibufenamide on HBsAg levels in patients with chronic hepatitis B: a 96-week real-world study].","authors":"L L Wang, J Chen, X Y Wang, Z S Liu, J Yu, J Q Yu, H F Zhang","doi":"10.3760/cma.j.cn501113-20250726-00294","DOIUrl":"10.3760/cma.j.cn501113-20250726-00294","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the effect of switching from entecavir (ETV) to tenofovir amibufenamide (TMF) on hepatitis B surface antigen (HBsAg) levels in patients with chronic hepatitis B. <b>Methods:</b> Patients with chronic hepatitis B were enrolled and assigned to two groups after 48 weeks of ETV therapy. One group continued ETV treatment, whereas the other group switched to TMF. HBsAg levels were compared between the two groups of patients after continuous follow-up through week 96. Treatment efficacy was evaluated based on virological response, serological markers, and others. Independent-samples <i>t</i>-tests, repeated-measures analysis of variance (ANOVA), and the Mann-Whitney <i>U</i> test were used to compare continuous variables, while the <i>χ</i><sup>2</sup> test was used to compare categorical variables between the groups. <b>Results:</b> Seventy-eight patients in the ETV-continuation group and seventy-four in the ETV-to-switch-TMF group completed the 96-week follow-up. There were no statistically significant differences in hepatitis B surface antigen levels (HBsAg), hepatitis B e antigen (HBeAg) status, or hepatitis B virus (HBV) DNA levels between the two groups at baseline and 48 weeks (<i>P</i>>0.05). HBsAg levels decreased from (2.99±0.85) log<sub>10</sub> IU/mL to (2.82±0.88) log<sub>10</sub> IU/mL over 96 weeks in the ETV-continuation group (<i>P</i>=0.500). HBsAg levels dropped from (3.12±0.74) log<sub>10</sub> IU/mL to (2.64±0.63) log<sub>10</sub> IU/mL over 96 weeks in the ETV-to-switch-TMF group (<i>P</i><0.001). The reduction in HBsAg levels was significantly higher in the ETV-to-switch-TMF group compared with the ETV-continuation group following 96 weeks [(0.48±0.07) log<sub>10</sub> IU/mL vs. (0.17±0.05) log<sub>10</sub> IU/mL, <i>P</i><0.001]. The proportion of HBeAg-positive patients in the ETV-continuation group was 32.1% (25/78), 28.2% (22/78), and 24.4% (19/78) at baseline, 48 weeks, and 96 weeks, respectively. The proportion of HBeAg-positive patients in the ETV-to-switch-TMF group was 40.5% (30/74), 39.2% (29/74), and 31.1% (23/74) at baseline, 48 weeks, and 96 weeks, respectively. There was no statistically significant difference in the HBeAg seroconversion rate between the two groups of patients (<i>χ</i><sup>2</sup>=0.003, <i>P</i>=0.954). Seventy-four patients in the ETV-continuation group (74/78, 94.9%) and seventy-one patients in the ETV-to-switch-TMF group (71/74, 95.9%) achieved undetectable HBV DNA levels at the completion of the 96-week follow-up, with no statistically significant difference in both groups of patients for achieving HBV DNA negativity (<i>P</i>=0.961). Compared with baseline, serum creatinine levels showed an upward trend in the ETV-continuation and ETV-to-switch-TMF groups after 96 weeks of treatment; however, the differences were not statistically significant (<i>P</i>>0.05). In addition, there were no statistically significant differences in triglyceride or total cholest","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 9","pages":"886-892"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research advances in immune and metabolic dysregulation in the diagnosis and treatment of acute-on-chronic liver failure].","authors":"S R Wang, H Jia, X Zhang, H Yang, J W Li, R Y Liu, M Shen, Z Z Han, X Y Wang, W Yuan, M Liu, L Zhou, Y Ran","doi":"10.3760/cma.j.cn501113-20260108-00016","DOIUrl":"10.3760/cma.j.cn501113-20260108-00016","url":null,"abstract":"<p><p>Acute-on-chronic liver failure (ACLF) has rapid onset and progression, with an extremely high short-term mortality rate. Accurate assessment and early intervention are crucial in clinical diagnosis and treatment. The core pathophysiological mechanisms of ACLF involve immune and metabolic dysregulation, which do not occur in isolation but instead interact through an \"immune-metabolic interaction axis,\" mutually driving each other and evolving dynamically. Immune dysregulation is characterized by a dynamic transition from a systemic hyperinflammatory state to immunosuppression, whereas metabolic dysregulation is centered on mitochondrial dysfunction, triggering the reprogramming of multiple metabolic pathways. The interplay between these processes creates a vicious cycle that collectively drives disease progression. In recent years, with the deepening of mechanism research, various immune-and metabolic-related biomarkers have been identified and gradually applied in clinical evaluation and treatment. This article systematically reviews the current research status of immune and metabolic dysregulation in patients with ACLF and explores the potential application prospects of related biomarkers in diagnosis and treatment.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 9","pages":"938-944"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Interventional therapeutic strategies for metastatic liver cancer].","authors":"X D Sun, L Jin","doi":"10.3760/cma.j.cn501113-20260527-00209","DOIUrl":"10.3760/cma.j.cn501113-20260527-00209","url":null,"abstract":"<p><p>Metastatic liver cancer is a common terminal manifestation of malignant neoplasms, with colorectal cancer liver metastasis (CRLM) being particularly prevalent. Surgical resection is applicable only to a small proportion of patients. In recent years, interventional therapy has become an important local treatment modality for patients with unresectable metastatic liver cancer, offering advantages such as minimal invasiveness, precision, and repeatability, thus supporting downstaging, bridging, and salvage therapy. The role of interventional therapy is shifting from terminal palliative care toward a systematic therapeutic strategy within a multidisciplinary comprehensive management framework, emphasizing individualized stratification based on tumor burden, hepatic function, and therapeutic objectives to facilitate intrahepatic tumor burden reduction, create a window for radical treatment, and enhance long-term patient survival.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 9","pages":"845-850"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[IOX1 alleviates hepatic ischemia-reperfusion injury by inhibiting mitogen-activated protein kinase signaling pathway].","authors":"S C Hu, Y G Lei, Y C Huang, H Q Liu, J Z Ge, K Ni, B Yang, X Xu","doi":"10.3760/cma.j.cn501113-20251219-00544","DOIUrl":"10.3760/cma.j.cn501113-20251219-00544","url":null,"abstract":"<p><p><b>Objective:</b> To explore and discuss the protective effects of 5-carbonyl-8-hydroxyquinoline (IOX1) potential mechanisms in the mouse model of hepatic ischemia-reperfusion injury (IRI) and <i>in vitro</i> hepatocyte hypoxia-reoxygenation (H/R). <b>Methods:</b> <i>In vivo</i> and <i>in vitro</i> models of liver injury were established using a mouse hepatic ischemia-reperfusion model and a primary hepatocyte hypoxia-reoxygenation (H/R) model. <i>In vivo</i> experiments were divided into three groups: sham group, IRI group, and IRI+IOX1 group. <i>In vitro</i> experiments were divided into four groups: negative control group (CTRL), CTRL+IOX1 group, H/R group, and H/R+IOX1 group. Liver injury was assessed by measuring serum liver enzyme levels, hematoxylin-eosin (HE) staining, and immunohistochemistry. Apoptosis and oxidative stress were evaluated using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay, flow cytometry, real-time quantitative PCR, and reactive oxygen species (ROS) fluorescence staining. Differentially expressed genes were screened by RNA sequencing of liver tissues, and the expression levels of differential proteins were validated by western blotting. Data were processed using GraphPad Prism 10.0. <b>Results:</b> Compared with the IRI group, the IRI+IOX1 group showed significantly lower levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). At an IOX1 dose of 2 mg/kg, ALT and AST levels decreased by 87.05% and 94.49%, respectively (<i>P</i><0.000 1), and hepatic histopathological damage was markedly ameliorated. Immunohistochemical staining results revealed less inflammatory cell infiltration in the IRI+IOX1 group. TUNEL assay, western blotting, and real-time quantitative PCR results demonstrated that IOX1 treatment reduced apoptosis after hepatic I/R injury. In the <i>in vitro</i> model, flow cytometry and western blotting results showed that IOX1 reduced apoptosis in primary hepatocytes after H/R injury, and ROS staining results indicated that IOX1 decreased ROS production following H/R injury. RNA sequencing and western blotting results revealed that IOX1 regulated the mitogen-activated protein kinase signaling pathway in hepatocytes by inhibiting AlkB homolog 5 (ALKBH5). <b>Conclusion:</b> IOX1 regulates the extracellular signalregulated kinase (ERK)/p38 mitogen-activated protein kinase (MAPK) signaling pathway by inhibiting ALKBH5 in hepatocytes, thereby reducing hepatocyte apoptosis and inflammatory responses and attenuating liver injury following ischemia-reperfusion.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 9","pages":"903-911"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Surgical treatment of metastatic liver cancer: the biological-behavioral basis of \"homotherapy for heteropathy\"].","authors":"W Zhang, B C Xing","doi":"10.3760/cma.j.cn501113-20260524-00201","DOIUrl":"10.3760/cma.j.cn501113-20260524-00201","url":null,"abstract":"<p><p>The incidence rate of secondary malignant liver tumors exceeds that of primary liver cancer. Approximately 25% to 50% of patients with solid tumors develop liver metastases during the course of their disease, which has become a key factor limiting the prognosis of patients with malignant tumors. Historical perspectives were constrained by the initial edition of the American Joint Committee on Cancer (AJCC) staging system in the 1970s, which uniformly classified liver metastases as incurable at Stage IV.This classification biologically defined the \"nihilism\" of local surgical intervention. In recent years, with the deepening study of tumor molecular biology, along with advances in systemic therapies, improvements in imaging, surgical techniques, and local treatments such as surgery, ablation, interventional therapy, and radiotherapy have significantly extended survival for patients with favorable biological behavior who have metastatic liver cancer. This paper discusses the epidemiological status of secondary malignant tumors, the biological basis for \"homotherapy for heteropathy,\" and the currently recognized surgical treatment measures for favorable biological behavior, along with their associated survival benefits for metastatic liver cancer. Standardized and individualized local treatment of metastatic liver cancer relies on continued advances in multidisciplinary cooperation. Therefore, treatment strategies based on biological characteristic stratification can help improve patient survival rates and have the potential to alter clinical outcomes, shifting from palliative care toward curative goals for liver metastasis.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 9","pages":"828-835"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A transition from targeting immune evasion to a multidisciplinary collaborative treatment framework for \"homotherapy for heteropathy\" in liver metastases].","authors":"Q Zhang, N Zhang, Y Y Lu","doi":"10.3760/cma.j.cn501113-20260601-00224","DOIUrl":"10.3760/cma.j.cn501113-20260601-00224","url":null,"abstract":"<p><p>Liver metastasis is a common and challenging clinical problem in the progression of various solid tumors. The current diagnostic and therapeutic scheme is primarily formulated according to the pathological classification and molecular stratification of the primary tumor. However, once tumors of different origins metastasize to the liver, they may face common challenges such as limited benefit from immune checkpoint inhibitors, inadequate and unsustained disease control with systemic therapy, and recurrence following local treatment. The liver's immunologically tolerogenic background, together with impaired antigen presentation, restricted effector immune responses, myeloid-mediated immunosuppression, abnormal vasculature, stromal remodeling, and metabolic competition, may contribute to organ-specific therapeutic resistance that is shared across different cancer types after hepatic metastasis. Based on a review of relevant mechanisms, clinical evidence, and limitations of existing treatment paradigms, a clinical decision-making framework for \"homotherapy for heteropathy\" in liver metastases is proposed. Systemic therapies-including chemotherapy, targeted therapy, and immunotherapy-are integrated with local therapies, including surgery, ablation, interventional therapy, and radiotherapy, together with supportive care to address potentially shared organ-specific therapeutic resistance following liver metastasis in line with standardized classification and treatment of the primary tumor. Treatment is dynamically adjusted according to disease status and treatment response, with the integration and implementation of systemic and local therapies, therapeutic goals, and treatment sequencing. This framework is primarily applicable to patients with resectable or amenable-to-ablation oligometastatic disease, initially unresectable disease with the potential for conversion to resectability, liver-dominant disease with stable extrahepatic disease, and patients with limited residual intrahepatic disease or oligoprogression following systemic therapy. Clinical applications should still consider the biological characteristics of the primary cancer, the status of liver and extrahepatic disease, prior treatment responses, liver function reserve, and the available evidence base. The \"homotherapy for heteropathy\" framework uses shared organ-specific therapeutic resistance as an entry point-based on cancer-specific treatments-to facilitate patient stratification, multidisciplinary collaboration, and the optimization of treatment sequencing. In the future, domestic multicenter prospective studies and real-world cohorts will be needed to further clarify the suitable patient population, treatment timing, and biomarkers of benefit.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 9","pages":"817-827"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The E3 ubiquitin ligase KLHL8 degrades HBx protein via the ubiquitin-proteasome pathway and inhibits HBV cccDNA transcription].","authors":"Z H Liu, X M He, B Zhao, J Q Li, K X Xu, H B Yu, J Chen","doi":"10.3760/cma.j.cn501113-20260414-00151","DOIUrl":"10.3760/cma.j.cn501113-20260414-00151","url":null,"abstract":"<p><p><b>Objective:</b> To screen for host factors involved in the degradation of hepatitis B virus X protein (HBx) and to investigate whether they affect hepatitis B virus (HBV) replication by modulating HBx stability. <b>Methods:</b> HuProt™ human proteome microarrays were used to screen for HBx-interacting proteins, combined with bioinformatics analysis focusing on E3 ligases within the ubiquitin-proteasome system. The effects of candidate proteins on HBx stability were validated by western blotting, HiBiT activity assays, cycloheximide chase assays, and proteasome inhibitor treatment. In an HBV infection model, quantitative PCR, enzyme-linked immunosorbent assay, chromatin immunoprecipitation, and micrococcal nuclease assays were employed to assess the effects of the E3 ligase on the transcriptional activity of covalently closed circular DNA (cccDNA), viral replication, and epigenetic status. Intergroup comparisons were performed using one-way ANOVA, Student's <i>t</i>-test, or the non-parametric Mann-Whitney <i>U</i> test as appropriate. <b>Results:</b> A total of 290 HBx-interacting candidate proteins were identified. Among them, the ubiquitin-proteasome system-related proteins Kelch-like protein 8 (KLHL8) and the canonical HECT-type E3 ligase WWP2 significantly reduced HBx protein levels and, more notably, suppressed cccDNA-mediated viral transcription. Cycloheximide chase assays demonstrated that KLHL8 overexpression markedly shortened the half-life of HBx, and this effect was reversed by a 26S proteasome inhibitor, whereas WWP2 had a comparatively limited effect on the degradation rate of HBx. Functional experiments showed that KLHL8 overexpression inhibited cccDNA transcriptional activity and viral replication, reduced HBx binding to cccDNA, and decreased chromatin accessibility. <b>Conclusion:</b> The E3 ubiquitin ligase KLHL8 degrades HBx through the ubiquitin-proteasome pathway, thereby inhibiting HBV cccDNA transcription and replication. These findings provide a theoretical basis for novel anti-HBV strategies targeting the host ubiquitination machinery.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 9","pages":"868-877"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical study of serum N-terminal propeptide of type Ⅲ collagen combined with platelet count for the diagnosis of chronic hepatitis B-related liver fibrosis].","authors":"X Bai, L Zhu, M H Zheng, F J Rui, N Geng, Q Q Chen, J Xia, J Li","doi":"10.3760/cma.j.cn501113-20260130-00051","DOIUrl":"10.3760/cma.j.cn501113-20260130-00051","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; The development of advanced liver fibrosis in patients with chronic hepatitis B (CHB) significantly increases the risk of cirrhosis and liver cancer; therefore, early diagnosis is crucial for improving prognosis. Accordingly, this study established a diagnostic model combining serum N-terminal pro-peptide of type Ⅲ collagen (PRO-C3) and platelet count (PLT) to enhance the diagnostic performance for advanced liver fibrosis in CHB patients. &lt;b&gt;Methods:&lt;/b&gt; This study included CHB patients who had not received prior treatment and underwent liver biopsy at the Drum Tower Hospital affiliated with the Medical School of Nanjing University and Suzhou Fifth People's Hospital between October 15, 2017, and December 30 2021. Logistic regression analysis was used to identify risk factors for advanced liver fibrosis in patients with CHB and to establish a non-invasive model. The model's performance was evaluated using receiver operating characteristic (ROC) curves and decision curve analysis, while the DeLong test was employed to assess whether differences in the areas under the receiver operating characteristic curves (AUCs) among the non-invasive scores were statistically significant. &lt;b&gt;Results:&lt;/b&gt; Data from a total of 324 patients were included in the study, of whom 83 patients (25.6%) had advanced liver fibrosis. Multivariate logistic regression analysis revealed that PRO-C3 (odds ratio=1.04, &lt;i&gt;P&lt;/i&gt;&lt;0.01) and PLT (odds ratio=0.99, &lt;i&gt;P&lt;/i&gt;=0.04) were independent occurrence risk factors for advanced liver fibrosis in patients with CHB. The diagnostic model for advanced liver fibrosis based on PRO-C3 combined with PLT had an area under the receiver operating characteristic curve (AUC) of 0.80 (95% confidence interval [&lt;i&gt;CI&lt;/i&gt;], 0.74-0.85) in the training cohort, which was significantly higher than that of the Fibrosis-4 index (FIB-4) (AUC, 0.67; 95%&lt;i&gt;CI&lt;/i&gt;, 0.60-0.73; &lt;i&gt;P&lt;/i&gt;&lt;0.01) and the aspartate aminotransferase-to-platelet ratio index (APRI) (AUC, 0.71; 95%&lt;i&gt;CI&lt;/i&gt;, 0.65-0.77; &lt;i&gt;P&lt;/i&gt;=0.02). The differences in AUCs between the diagnostic model and the aforementioned non-invasive scores were statistically significant. Furthermore, the combined model demonstrated stable diagnostic performance across various clinical subgroups, including gender, age, alanine aminotransferase levels, HBeAg status, and HBV DNA levels (AUC: 0.73-0.84). The combined model and the aforementioned subgroups achieved favorable diagnostic performance in the validation cohort for advanced liver fibrosis in patients with CHB, with an AUC of 0.84 (95%&lt;i&gt;CI&lt;/i&gt;, 0.75-0.91) and (AUC: 0.78-0.94), respectively. &lt;b&gt;Conclusion:&lt;/b&gt; The non-invasive diagnostic model established by combining serum PRO-C3 and PLT shows favorable diagnostic value for CHB-related advanced liver fibrosis, and its performance is superior to commonly used non-invasive scores such as the Fibrosis-4 index and the aspartate aminotransferase-to-platelet ratio index. This simple and re","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 9","pages":"878-885"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[TACE-HAIC versus HAIC combined with targeted immunotherapy for unresectable hepatocellular carcinoma: a propensity score-matched retrospective controlled study].","authors":"C Liu, M Zhao, J Li, K Zhao, L Zheng, J C Xiao","doi":"10.3760/cma.j.cn501113-20250920-00399","DOIUrl":"10.3760/cma.j.cn501113-20250920-00399","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the safety profile and efficacy of transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) and HAIC combined with targeted immunotherapy in patients with unresectable hepatocellular carcinoma (uHCC). <b>Methods:</b> Clinical data of patients with uHCC who received TACE-HAIC or HAIC as the initial local therapy from January 2020 to December 2023 were retrospectively analyzed. Propensity score matching (PSM) was used to compare tumor response, progression-free survival (PFS), overall survival (OS), and adverse events between the two groups. Univariate and multivariate analyses of survival were performed using <i>t</i>-tests, <i>χ</i>² tests, Kaplan-Meier curves, or Cox proportional hazards models, according to the varied data. <b>Results:</b> A total of 258 cases were included, with 41 in the HAIC group and 217 in the TACE-HAIC group. Forty-one matched pairs of patients after PSM (<i>n</i>=41 in the HAIC group and <i>n</i>=82 in the TACE-HAIC group) were obtained. The results showed that the objective response rate (ORR) (70.7% vs. 51.2%, <i>P</i>=0.033) and the disease control rate (90.2% vs. 75.6%, <i>P</i>=0.030) were significantly superior in the TACE-HAIC group than in the HAIC group. The PFS (median 12.7 months vs. 7.9 months, <i>P</i>=0.006) and OS (median 24.4 months vs. 18.9 months, <i>P</i>=0.039) were also significantly prolonged in the TACE-HAIC group. There was no statistically significant difference in the incidence of grade 3/4 adverse events between the two groups. <b>Conclusion:</b> Compared with HAIC combined with targeted immunotherapy, TACE-HAIC combined with targeted immunotherapy shows superior tumor control and survival benefits in uHCC, with a favorable safety profile.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 9","pages":"858-867"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Recent advances in epidemiology, prevention and treatment of hepatitis C in China].","authors":"J J Yu, L Zhao, G W Ding, S D Ye, J Han, Z F Liu, W J Yan, J Li","doi":"10.3760/cma.j.cn501113-20260330-00126","DOIUrl":"10.3760/cma.j.cn501113-20260330-00126","url":null,"abstract":"<p><p>Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) that can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma, and it is one of the main causes of liver disease-related deaths globally and in China. The prevention and control of hepatitis C have consistently been priorities in China. A national seroepidemiological survey conducted in 2020 showed that the weighted prevalence of anti-HCV positivity among individuals aged 1-69 years in China was 0.28%, while the weighted prevalence of HCV RNA positivity was 0.15%, corresponding to an estimated 5.54 million individuals with anti-HCV positivity and 3.22 million individuals with HCV RNA positivity. Compared with the 2006 survey, the weighted prevalence of anti-HCV positivity decreased by 35%, indicating that substantial progress has been made in hepatitis C prevention and control in China. However, due to the large population size, the absolute number of infected individuals remains considerable. The introduction of direct-acting antiviral agents (DAAs) has transformed hepatitis C into a curable disease. In recent years, the inclusion of multiple DAAs in the National Medical Insurance Drug List has improved patients' access to antiviral therapy.The National Health Commission and nine other departments jointly issued the Work Plan for the Action to Eliminate the Public Health Hazard of Hepatitis C (2021-2030) in 2021, and the National Disease Control and Prevention Administration and nine other departments jointly released the Action Plan for Viral Hepatitis Prevention and Care (2025-2030) in 2025, providing policy support and planning for hepatitis C elimination in China. This article systematically reviews the current epidemiological status, disease burden characteristics, progress in prevention and treatment, and major challenges faced, providing a reference for advancing efforts to eliminate the public health threat posed by hepatitis C based on updated epidemiological data and recent developments in prevention and treatment in China.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 9","pages":"912-916"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}